Swetha R Kanduri,Nicholas Carbajal,Juan Carlos Q Velez
Swetha R Kanduri
Nrf2 Activation in the Glomeruli and Podocytes: Deciphering the Renal Mechanisms of Nrf2 [0.03%]
肾小球和足细胞中NRF2的活化：解密NRF2的肾脏机制
Arnaldo Lopez-Ruiz,Kiran Chandrashekar,Luis A Juncos
Arnaldo Lopez-Ruiz
The Mounting Evidence for Permissive Hypercreatinemia in Acute Heart Failure: Adding Sodium Glucose Cotransporter Inhibitors to the List [0.03%]
急性心力衰竭中支持性高血 creatinin 的证据越来越多：钠-葡萄糖共转运蛋白抑制剂也应列入其中
Etienne Macedo,Nicholas Wettersten
Etienne Macedo
Severity of Coexisting Diabetic Glomerular Lesions Affects Outcomes in Primary Glomerular Disease [0.03%]
并存的糖尿病性肾小球病变的程度影响原发性肾小球病的预后
Sudhir Perincheri
Sudhir Perincheri
Lori-Ann Fisher,Racquel Lowe-Jones
Lori-Ann Fisher
Managing Phosphate Burden in Patients Receiving Dialysis: Beyond Phosphate Binders and Diet [0.03%]
透析患者的磷负担管理：不仅仅是磷结合剂和饮食的问题
Kamyar Kalantar-Zadeh,Derek Forfang,George Bakris et al.
Kamyar Kalantar-Zadeh et al.
Most patients receiving dialysis rely on dietary restriction and phosphate binders to minimize the risk of hyperphosphatemia, which is associated with increased mortality. However, dietary restriction is difficult because of hidden phosphat...
Molecular Phenotyping and Mechanisms of Myocardial Fibrosis in Advanced Chronic Kidney Disease [0.03%]
慢性肾脏病晚期心肌纤维化分子分型及机制研究
Gayatri Narayanan,Arvin Halim,Alvin Hu et al.
Gayatri Narayanan et al.
Key Points: Myocardial fibrosis in hearts from patients with CKD is characterized by increased trimeric tensile collagen type I and decreased elastic collagen type III compared with hearts from hypertensive or healthy do...
Nicole G Alindogan,Theodore H Yuo
Nicole G Alindogan
Intravascular Hemolysis and AKI in Children Undergoing Extracorporeal Membrane Oxygenation [0.03%]
儿童体外膜肺氧合的血管内溶血与急性肾损伤
Amy E Strong,Jarcy Zee,Rosanna Fulchiero et al.
Amy E Strong et al.
Key Points: The incidence of AKI while undergoing ECMO in pediatric patients is high and independently increases mortality.Laboratory markers consistent with intravascular hemolysis increase the hazard of a composite out...
Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study [0.03%]
为期26周的Tenapanor改善透析患者高血磷水平的疗效研究(NORMALIZE)
Arnold L Silva,Glenn M Chertow,German T Hernandez et al.
Arnold L Silva et al.
Key Points: Tenapanor is a first-in-class, minimally systemic sodium–hydrogen exchanger 3 inhibitor with a mechanism of action distinct from phosphate binders.Tenapanor alone or with phosphate binders led to 35%–49% of...